Skip to main content
SpringerLink
Log in

Kisspeptin and neurokinin B analogs use in gynecological endocrinology: where do we stand?

  • Review
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Background

Recent studies have found that kisspeptin/neurokinin B/dynorphin neurons (KNDy neurons) in the infundibular nucleus play a crucial role in the reproductive axis. Analogs, both agonists and antagonists, of kisspeptin and neurokinin B (NKB) are particularly important in explaining the physiological role of KNDy in the reproductive axis in animals. The use of kisspeptin and NKB analogs has helped elucidate the regulators of the hypothalamic reproductive axis.

Purpose

This review describes therapeutic uses of Kiss-1 and NKB agonists, most obviously the use of kisspeptin agonists in the treatment for infertility and the induction of ovulation. Kisspeptin antagonists may have potential clinical applications in patients suffering from diseases associated with enhanced LH pulse frequency, such as polycystic ovary syndrome or menopause. The inhibition of pubertal development using Kiss antagonists may be used as a therapeutic option in precocious puberty. Kisspeptin antagonists have been found capable of inhibiting ovulation and have been proposed as novel contraceptives. Hypothalamic amenorrhea and delayed puberty are conditions in which normalization of LH secretion may potentially be achieved by treatment with both kisspeptin and NKB agonists. NKB antagonists are used to treat vasomotor symptoms in postmenopausal women, providing rapid relief of symptoms while supplanting the need for exogenous estrogen exposure.

Conclusions

There is a wide spectrum of therapeutic uses of Kiss-1 and NKB agonists, including the management of infertility, treatment for PCOS, functional hypothalamic amenorrhea or postmenopausal vasomotor symptoms, as well as contraceptive issues. Nevertheless, further research is needed before kisspeptin and NKB analogs are fully incorporated in clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Skorupskaite K, George JT, Anderson RA (2014) The kisspeptin–GnRH pathway in human reproductive health and disease. Hum Reprod Update 20(4):485–500

    CAS  PubMed  PubMed Central  Google Scholar 

  2. Szeliga A, Czyzyk A, Podfigurna A, Genazzani AR, Genazzani AD, Meczekalski B (2018) The role of kisspeptin/neurokinin B/dynorphin neurons in pathomechanism of vasomotor symptoms in postmenopausal women: from physiology to potential therapeutic applications. Gynecol Endocrinol 34(11):1–7

    Google Scholar 

  3. West A, Vojta PJ, Welch DR, Weissman BE (1998) Chromosome localization and genomic structure of the KiSS-1 metastasis suppressor gene (KISS1). Genomics 54(1):145–148

    CAS  PubMed  Google Scholar 

  4. Roseweir AK, Millar RP (2008) The role of kisspeptin in the control of gonadotrophin secretion. Hum Reprod Update 15(2):203–212

    PubMed  Google Scholar 

  5. Cortés ME, Carrera B, Rioseco H, Pablo del Río J, Vigil P (2015) The role of kisspeptin in the onset of puberty and in the ovulatory mechanism: a mini-review. J Pediatr Adolesc Gynecol 28(5):286–291

    PubMed  Google Scholar 

  6. Tomita K, Oishi S, Cluzeau J et al (2007) SAR and QSAR studies on the N-terminally acylated pentapeptide agonists for GPR54. J Med Chem 50(14):3222–3228

    CAS  PubMed  Google Scholar 

  7. Tomita K, Oishi S, Ohno H, Peiper SC, Fujii N (2008) Development of novel G-protein-coupled receptor 54 agonists with resistance to degradation by matrix metalloproteinase. J Med Chem 51(23):7645–7649

    CAS  PubMed  Google Scholar 

  8. Roseweir AK, Millar RP (2013) Kisspeptin antagonists. Adv Exp Med Biol 784:159–186

    CAS  PubMed  Google Scholar 

  9. Roseweir AK, Kauffman AS, Smith JT et al (2009) Discovery of potent kisspeptin antagonists delineate physiological mechanisms of gonadotropin regulation. J Neurosci 29(12):3920–3929

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Corbett S, Shmorgun D, Claman P et al (2014) The prevention of ovarian hyperstimulation syndrome. J Obstet Gynaecol Canada 36(11):1024–1033

    Google Scholar 

  11. Thomsen L, Humaidan P (2015) Ovarian hyperstimulation syndrome in the 21st century. Curr Opin Obstet Gynecol 27(3):210–214

    PubMed  Google Scholar 

  12. Macklon NS, Stouffer RL, Giudice LC, Fauser BCJM (2006) The science behind 25 years of ovarian stimulation for in vitro fertilization. Endocr Rev 27(2):170–207

    PubMed  Google Scholar 

  13. Owens LA, Abbara A, Lerner A et al (2018) The direct and indirect effects of kisspeptin-54 on granulosa lutein cell function. Hum Reprod 33(2):292–302

    CAS  PubMed  Google Scholar 

  14. Whitlock BK, Daniel JA, Wilborn RR, Maxwell HS, Steele BP, Sartin JL (2010) Interaction of kisspeptin and the somatotropic axis. Neuroendocrinology 92(3):178–188

    CAS  PubMed  Google Scholar 

  15. Abbara A, Jayasena CN, Christopoulos G et al (2015) Efficacy of kisspeptin-54 to trigger oocyte maturation in women at high risk of ovarian hyperstimulation syndrome (OHSS) during in vitro fertilization (IVF) therapy. J Clin Endocrinol Metab 100(9):3322–3331

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Albers-Wolthers CHJ, de Gier J, Rutten VPMG et al (2016) The effects of kisspeptin agonist canine KP-10 and kisspeptin antagonist p271 on plasma LH concentrations during different stages of the estrous cycle and anestrus in the bitch. Theriogenology 86(2):589–595

    CAS  PubMed  Google Scholar 

  17. Caraty A, Decourt C, Briant C, Beltramo M (2012) Kisspeptins and the reproductive axis: potential applications to manage reproduction in farm animals. Domest Anim Endocrinol 43(2):95–102

    CAS  PubMed  Google Scholar 

  18. Whitlock BK, Daniel JA, Amelse LL, Tanco VM, Chameroy KA, Schrick FN (2015) Kisspeptin receptor agonist (FTM080) increased plasma concentrations of luteinizing hormone in anestrous ewes. PeerJ 3:e1382

    PubMed  PubMed Central  Google Scholar 

  19. Jayasena CN, Abbara A, Veldhuis JD et al (2014) Increasing LH pulsatility in women with hypothalamic amenorrhoea using intravenous infusion of kisspeptin-54. J Clin Endocrinol Metab 99(6):E953–E961

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Parker PA, Coffman EA, Pohler KG et al (2019) Acute and subacute effects of a synthetic kisspeptin analog, C6, on serum concentrations of luteinizing hormone, follicle stimulating hormone, and testosterone in prepubertal bull calves. Theriogenology 130:111–119

    CAS  PubMed  Google Scholar 

  21. Millar RP, Roseweir AK, Tello JA et al (2010) Kisspeptin antagonists: unraveling the role of kisspeptin in reproductive physiology. Brain Res 1364:81–89

    CAS  PubMed  Google Scholar 

  22. Li X-F, Kinsey-Jones JS, Cheng Y et al (2009) Kisspeptin signalling in the hypothalamic arcuate nucleus regulates gnrh pulse generator frequency in the rat. PLoS One 4(12):e8334

    PubMed  PubMed Central  Google Scholar 

  23. Junqueira FRR, Lara LAS, Martins WP et al (2015) Gonadotropin and estradiol levels after leuprolide stimulation tests in Brazilian girls with precocious puberty. J Pediatr Adolesc Gynecol 28(5):313–316

    PubMed  Google Scholar 

  24. Sahin Z, Canpolat S, Ozcan M, Ozgocer T, Kelestimur H (2015) Kisspeptin antagonist prevents RF9-induced reproductive changes in female rats. Reproduction 149(5):465–473

    CAS  PubMed  Google Scholar 

  25. Pineda R, Garcia-Galiano D, Roseweir A et al (2010) Critical roles of kisspeptins in female puberty and preovulatory gonadotropin surges as revealed by a novel antagonist. Endocrinology 151(2):722–730

    CAS  PubMed  Google Scholar 

  26. Albers-Wolthers CHJ, de Gier J, Walen M et al (2017) In vitro and in vivo effects of kisspeptin antagonists p234, p271, p354, and p356 on GPR54 activation. PLoS One 12(6):e0179156

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Aguirre RS, Eugster EA (2018) Central precocious puberty: from genetics to treatment. Best Pract Res Clin Endocrinol Metab 32(4):343–354

    PubMed  Google Scholar 

  28. Samir H, Nagaoka K, Watanabe G (2018) Effect of kisspeptin antagonist on goat in vitro Leydig cell steroidogenesis. Theriogenology 121:134–140

    CAS  PubMed  Google Scholar 

  29. Page NM (2005) New challenges in the study of the mammalian tachykinins. Peptides 26(8):1356–1368

    CAS  PubMed  Google Scholar 

  30. Navarro VM (2013) Interactions between kisspeptins and neurokinin B. Adv Exp Med Biol 784:325–347

    CAS  PubMed  Google Scholar 

  31. Rance NE, Krajewski SJ, Smith MA, Cholanian M, Dacks PA (2010) Neurokinin B and the hypothalamic regulation of reproduction. Brain Res 1364:116–128

    CAS  PubMed  PubMed Central  Google Scholar 

  32. Satake H, Kawada T (2006) Overview of the primary structure, tissue-distribution, and functions of tachykinins and their receptors. Curr Drug Targets 7(8):963–974

    CAS  PubMed  Google Scholar 

  33. Rance NE, Young WS (1991) Hypertrophy and increased gene expression of neurons containing neurokinin-B and substance-P messenger ribonucleic acids in the hypothalami of postmenopausal women*. Endocrinology 128(5):2239–2247

    CAS  PubMed  Google Scholar 

  34. Topaloglu AK, Reimann F, Guclu M et al (2009) TAC3 and TACR3 mutations in familial hypogonadotropic hypogonadism reveal a key role for neurokinin B in the central control of reproduction. Nat Genet 41(3):354–358

    CAS  PubMed  Google Scholar 

  35. Young J, Bouligand J, Francou B et al (2010) TAC3 and TACR3 defects cause hypothalamic congenital hypogonadotropic hypogonadism in humans. J Clin Endocrinol Metab 95(5):2287–2295

    CAS  PubMed  Google Scholar 

  36. Tusset C, Noel SD, Trarbach EB et al (2012) Mutational analysis of TAC3 and TACR3 genes in patients with idiopathic central pubertal disorders. Arq Bras Endocrinol Metabol 56(9):646–652

    PubMed  PubMed Central  Google Scholar 

  37. Wormser U, Laufer R, Hart Y, Chorev M, Gilon C, Selinger Z (1986) Highly selective agonists for substance P receptor subtypes. EMBO J 5(11):2805–2808

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Ramaswamy S, Seminara SB, Plant TM (2011) Evidence from the agonadal juvenile male rhesus monkey (Macaca mulatta) for the view that the action of neurokinin B to trigger gonadotropin-releasing hormone release is upstream from the kisspeptin receptor. Neuroendocrinology 94(3):237–245

    CAS  PubMed  PubMed Central  Google Scholar 

  39. Young J, George JT, Tello JA et al (2013) Kisspeptin restores pulsatile LH secretion in patients with neurokinin B signaling deficiencies: physiological, pathophysiological and therapeutic implications. Neuroendocrinology 97(2):193–202

    CAS  PubMed  Google Scholar 

  40. Rance NE, Dacks PA, Mittelman-Smith MA, Romanovsky AA, Krajewski-Hall SJ (2013) Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: a novel hypothesis on the mechanism of hot flushes. Front Neuroendocrinol 34(3):211–227

    CAS  PubMed  Google Scholar 

  41. Dacks PA, Krajewski SJ, Rance NE (2011) Activation of neurokinin 3 receptors in the median preoptic nucleus decreases core temperature in the rat. Endocrinology 152(12):4894–4905

    CAS  PubMed  PubMed Central  Google Scholar 

  42. Newton CL, Anderson RC, Millar RP (2016) Therapeutic neuroendocrine agonist and antagonist analogs of hypothalamic neuropeptides as modulators of the hypothalamic–pituitary–gonadal axis. Endocr Dev 30:106–129

    CAS  PubMed  Google Scholar 

  43. Dawson LA, Langmead CJ, Dada A et al (2010) In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics. Eur J Pharmacol 627(1–3):106–114

    CAS  PubMed  Google Scholar 

  44. Skorupskaite K, George J, Anderson RA (2015) Role of a neurokinin B receptor antagonist in the regulation of ovarian function in healthy women. Lancet 385(Suppl 1):S92

    PubMed  Google Scholar 

  45. Katulski K, Podfigurna A, Czyzyk A, Meczekalski B, Genazzani AD (2018) Kisspeptin and LH pulsatile temporal coupling in PCOS patients. Endocrine 61(1):149–157

    CAS  PubMed  PubMed Central  Google Scholar 

  46. George JT, Kakkar R, Marshall J et al (2016) Neurokinin B receptor antagonism in women with polycystic ovary syndrome: a randomized, placebo-controlled trial. J Clin Endocrinol Metab 101(11):4313–4321

    CAS  PubMed  Google Scholar 

  47. Jayasena CN, Comninos AN, Stefanopoulou E et al (2015) Neurokinin B administration induces hot flushes in women. Sci Rep 5(1):8466

    CAS  PubMed  PubMed Central  Google Scholar 

  48. Modi M, Dhillo WS (2019) Neurokinin 3 receptor antagonism—a novel treatment for menopausal hot flushes. Neuroendocrinology 109(3):242–248

    CAS  PubMed  Google Scholar 

  49. Prague JK, Roberts RE, Comninos AN et al (2017) Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet (Lond, Engl) 389(10081):1809–1820

    CAS  Google Scholar 

  50. Prague JK, Roberts RE, Comninos AN et al (2018) Neurokinin 3 receptor antagonism rapidly improves vasomotor symptoms with sustained duration of action. Menopause 25(8):862–869

    PubMed  PubMed Central  Google Scholar 

  51. Skorupskaite K, George JT, Veldhuis JD, Millar RP, Anderson RA (2018) Neurokinin 3 receptor antagonism reveals roles for neurokinin B in the regulation of gonadotropin secretion and hot flashes in postmenopausal women. Neuroendocrinology 106(2):148–157

    CAS  PubMed  Google Scholar 

  52. Anderson RA, Skorupskaite K, Sassarini J (2019) The neurokinin B pathway in the treatment of menopausal hot flushes. Climacteric 22(1):51–54

    CAS  PubMed  Google Scholar 

Download references

Funding

No external funding was either sought or obtained for this study.

Author information

Authors and Affiliations

  1. Department of Gynecological Endocrinology, Poznan University of Medical Sciences, 33 Polna Street, 60-535, Poznan, Poland

    A. Szeliga, A. Podfigurna, G. Bala & B. Meczekalski

Authors
  1. A. Szeliga
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Podfigurna
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Bala
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B. Meczekalski
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B. Meczekalski.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This manuscript is a review of the literature and does not contain original research either on animal or on human subjects.

Informed consent

For this type of study, informed consent is not required.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Szeliga, A., Podfigurna, A., Bala, G. et al. Kisspeptin and neurokinin B analogs use in gynecological endocrinology: where do we stand?. J Endocrinol Invest 43, 555–561 (2020). https://doi.org/10.1007/s40618-019-01160-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40618-019-01160-0

Keywords

Search

Navigation